SynthesisFrontiers in pharmacology2025
Knowledge domain and evolutionary trends of P2Y receptors in cardiovascular diseases: a bibliometric and altmetric analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study employs a dual-metric framework integrating bibliometric and altmetric analyses to systematically map the knowledge domain and structural evolution of P2Y receptor research in cardiovascular diseases (CVDs) from 2005 to 2025. Methods: Data were systematically retrieved from the Web of Science Core Collection, Scopus, PMC, and Altmetric databases. By integrating network visualization (CiteSpace, VOSviewer), descriptive bibliometrics, and qualitative content analysis, this study mapped the structural evolution of the research landscape. Additionally, the correlation between scholarly impact and social visibility was quantified using Spearman analysis. Results: Our analysis encompassed 2,591 articles published between 2005 and 2025, from which the top 100 based on citation count and Altmetric Attention Score (AAS) were selected. The annual publication volume demonstrates sustained growth. The USA contributed 941 articles and holds a leading position, with scholars such as Dominick J. Angiolillo (132 articles) forming a core collaborative network focused on the clinical translation of P2Y Conclusion: P2Y receptor research has transformed from a singular antithrombotic focus into a multidimensional regulatory network. While P2Y
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.